Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study

BJU International

Volumn 93, Issue 1, 2004, Pages 71-77

  Chapple, C R ^a   Arano P ^b   Bosch, J L H R ^c   De Ridder, D ^d   Kramer, A E J L ^e   Ridder, A M ^f  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b FUNDACIÓ PUIGVERT   (Spain)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e BG UNFALLKLINIK MURNAU   (Germany)

^f ASTELLAS PHARMA INC   (Japan)

Author keywords

Muscarinic receptor antagonist; Overactive bladder; Solifenacin succinate; Tolerability; Tolterodine; YM905

Indexed keywords

PLACEBO; SOLIFENACIN; TOLTERODINE;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR MUSCLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRY NOSE; DYSPEPSIA; DYSURIA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; STATISTICAL ANALYSIS; SWEATING; TREATMENT OUTCOME; URINARY URGENCY; URINE RETENTION; VISUAL IMPAIRMENT; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; QUINUCLIDINES; SINGLE-BLIND METHOD; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER DISEASES; URINARY RETENTION; URINATION;

EID: 1642538375     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04561.x     Document Type: Article

References (19)

1. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Rovner ES, Wein AJ. Incidence and prevalence of overactive bladder. Curr Urol Rep 2002; 3: 434-8
3. Milsom I, Stewart W, Thüroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6 (Suppl.): S565-73
4. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Medical 1999; 44: 56-66
5. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 (Suppl.): S580-90
6. Davila GW, Neimark M. The overactive bladder, prevalence and effects on quality of life. Clin Obstet Gynecol 2002; 45: 173-81
7. Nilvebrant L, Andersson KE, Mattiasson A. Characterization of the muscarinic cholinoceptors in the human detrusor. J Urol 1985; 134: 418-23
8. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 33-46
9. Appell RA, Sand P, Dmochowski R et al. for the OBJECT Study Group. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358-63
10. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988-93
11. Smulders RA, Krauwinkel W, Abila B, van Zijtveld J. 10-and 20-mg oral doses of YM905, a novel, bladder-selective antimuscarinic; pharmacokinetics, pharmacodynamics, and safety in healthy elderly men and women. Neurourol Urodyn 2002; 4: 295-6
12. Smulders RA, Tan HT, Krauwinkel W, Abila B, van Zijtveld J. A placebo controlled, dose-rising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of YM905. Neurourol Urodyn 2002; 4: 297-8
13. Smulders RA, van Alphen WW, Visser JN, Abila B, van Zijtveld J. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men. Safety, tolerability and pharmacokinetics. Neurourol Urodyn 2002; 4: 298-9
14. Kuipers M, Tran DD, Krauwinkel W, Abila B, Mulder H. Absolute bioavailability of YM905 in healthy male volunteers: a single-dose, randomized, two-period crossover study. Neurourol Urodyn 2002; 4: 296-7
15. Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. N-S Arch Pharmacol 2002; 366: 97-103
16. Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326: 841-4
17. Versi E, Appell R, Mobley D et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000; 95: 718-21
18. Diokno AC, Appell RA, Sand PK et al. for the OPERA Trial. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA Trial. Mayo Clin Proc 2003; 78: 687-95
19. Smith N, Grimes I, Ridge S, Tempel D, Uchida T. YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study. In Kramer G ed. ICS Proceedings. Heidelberg, Germany 2002: 138-9